Abstract

One in five people will have urticaria, a common inflammatory skin condition. The presence of urticaria, angioedema, or both of these symptoms is indicative of it. Using the Urticaria activity score 7, we will determine whether Omalizumab is safe and effective in treating chronic spontaneous urticaria. Material and Methods: This study is a prospective study that utilizes non-probability convenience sampling. The study employed a sample size of 20. This was the one year study conducted between the August 2016 to July 2017. This study was done at Department of Dermatology, Madha Medical College, Chennai, Tamil Nadu, India. Results: The prevalence of CSU was highest among individuals aged 20-40 years, which aligns with the findings of Maurer et al., where the most prevalent age group affected was also 20-40 years. The female-to-male ratio was 3:1, indicating a modest increase compared to the ratio of 2:1. The majority of ladies were homemakers. Angioedema does not show any correlation with age, sex, serum IgE level, or absolute eosinophil count. In our study, the occurrence of ASST positivity was 6.7%, which is lower compared to the occurrence of ASST positivity in patients with chronic urticaria in other studies, ranging from 35% to 58%. There was no correlation observed between the duration of time, the quantity of urticarial lesions, and the frequency of urticaria episodes each week. Conclusion: The study observed no association between angioedema, serum IgE levels, and absolute eosinophil count with age or sex. There was no correlation between the incidence, duration, and number of lesions per day in cases with urticaria. The treatment resulted in a notable enhancement of UAS7 after 12 weeks, but, no substantial progress was observed throughout the subsequent monitoring period.

Description